|
Report Date : |
07.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
PHARMEVO (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
402, Business Avenue, P.E.C.H.S., Block 6, Main Shahrah-e-Faisal,
Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1997 |
|
|
|
|
Com. Reg. No.: |
0038417 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
|
|
|
|
No. of Employees : |
188 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
pakistan - ECONOMIC OVERVIEW
Decades of
internal political disputes and low levels of foreign investment have led to
slow growth and underdevelopment in Pakistan. Agriculture accounts for more
than one-fifth of output and two-fifths of employment. Textiles account for
most of Pakistan's export earnings, and Pakistan's failure to expand a viable
export base for other manufactures has left the country vulnerable to shifts in
world demand. Official unemployment is 6%, but this fails to capture the true
picture, because much of the economy is informal and underemployment remains
high. Over the past few years, low growth and high inflation, led by a spurt in
food prices, have increased the amount of poverty - the UN Human Development
Report estimated poverty in 2011 at almost 50% of the population. Inflation has
worsened the situation, climbing from 7.7% in 2007 to more than 13% for 2011,
before declining to 9.3% at year-end. As a result of political and economic
instability, the Pakistani rupee has depreciated more than 40% since 2007. The
government agreed to an International Monetary Fund Standby Arrangement in
November 2008 in response to a balance of payments crisis. Although the economy
has stabilized since the crisis, it has failed to recover. Foreign investment
has not returned, due to investor concerns related to governance, energy,
security, and a slow-down in the global economy. Remittances from overseas
workers, averaging about $1 billion a month since March 2011, remain a bright
spot for Pakistan. However, after a small current account surplus in fiscal
year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit
in the second half of 2011, spurred by higher prices for imported oil and lower
prices for exported cotton. Pakistan remains stuck in a low-income, low-growth
trap, with growth averaging 2.9% per year from 2008 to 2011. Pakistan must
address long standing issues related to government revenues and energy
production in order to spur the amount of economic growth that will be
necessary to employ its growing population. Other long term challenges include
expanding investment in education and healthcare, and reducing dependence on
foreign donors.
|
Source : CIA |
PHARMEVO (PRIVATE) LIMITED
Registered Address
|
|
402, Business Avenue, P.E.C.H.S., Block 6, Main Shahrah-e-Faisal,
Karachi, Pakistan |
|
Tel # |
92 (21) 34315195 - 97 (3 Lines) |
|
Fax # |
92 (21) 34556344 |
|
Email |
|
a. |
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1997 |
|
c. |
Registration # |
0038417 |
|
Address |
Plot No. A-29, North Western Industrial Zone, Port Qasim, Karachi,
Pakistan |
|
Tel # |
92 (21) 34750483 - 86 (3 Lines) |
|
Fax # |
92 (21) 34750487 |
Saeed Methani Mushtaq & Co.
(Chartered
Accountants)
Office # 3, 1st Floor, Rajan Plaza, F-10 Markaz Islamabad,
Pakistan
Subject Company was established as a Private Limited Company in 1997
|
6. |
Authorized Capital |
Rs. 50,000,000/- divided into 5,000,000 shares
of Rs. 10/- each |
|
|
Issued & Paid up Capital |
Rs. 50,000,000/- divided into 5,000,000 shares
of Rs. 10/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Muhammad Haroon Qassim Mr. Zamiruddin Ahmed Mr. Austin Micheal Taylor Mr. Derek Alan Evans |
Pakistani Pakistani Pakistani Pakistani |
84, Jinnah
Co-operative Housing Society, Tipu Sultan Road, Karachi 37, Faran
Co-operative Society, Off: Shaheed-e-Millat Road, Karachi The Maples 1 Whittington Close Sand Batch Chesire, United Kingdom Rowan House, 9 Kingswood Palace, High Wycombe, Bucks, HP 13 7 SR,
United Kingdom |
Business Business Business Business |
Chief Executive Director Director Director |
|
Names |
No of Shares |
|
Mr. Zamiruddin Ahmed Mr. Ebrahim Qassim Mrs. Kulsoom Bano Mr. Muhammad Haroom Qassim Mrs. Zohra Bano Mr. Muhammad Jamil Qassim Mrs. Saba Qassim Mr. Austin Micheal Taylor Mr. Derek Alan Evans |
01 1,250 385,000 2,122,399 12,600 107,908 250,000 2,118,750 1,046 |
Subsidiary
None
Associated Companies
(1)
English
Biscuits (Pvt) Limited, Pakistan.
(2)
National
Foods Limited, Pakistan.
(3)
Shield
Corporation Limited, Pakistan.
(4)
Zaman
Textile Mills Limited, Pakistan.
(5)
Premier
Distributors, Pakistan.
(6)
Premier
Agencies, Pakistan.
Manufacture &
marketing of Pharmaceutical Products. Their brand names are ACELAR,
ACTIFLOR, AIREEZ, ANEX, BONEDOL, BONGARD, CERIZINE, DIU-TANSIN, EPIK, EPIMATE,
ESTAR, EVODOXIM, EVOFIX, EVOPRIDE, EVOROX, EVOTAXIME, EVOZID, FASTESO, FERRUM,
FREEDEP, GABIN, HEXA
188
(1)
ROQUETTE
INTERNATIONAL, FRANCE.
(2)
PURAC
(3)
YUNG SHIN
PHARM IND CO. LTD, TAIWAN.
(4)
HETERO
DRUGS, INDIA.
(5) DR. REDDYS, INDIA.
The capacity and production of the company’s plant is
indeterminable as it involves varying processes of manufacture.
|
Year |
In Pak Rupees |
|
2011 |
670,000,000/- (Estimated) |
Mainly exist at major cities of Pakistan
(1)
Soneri Bank
Limited, Pakistan.
(2)
Standard
Chartered Bank, Pakistan.
(3)
Faysal Bank
Limited, Pakistan.
(4)
Bank Alhabib
Limited, Pakistan.
(5)
Bank
Alfalah Limited, Pakistan.
· Karachi Chamber of Commerce & Industry.(KCCI)
· Pakistan Pharmaceutical Manufacturers Association.(PPMA)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 99.75 |
|
UK Pound |
1 |
Rs. 153.00 |
|
Euro |
1 |
Rs. 130.35 |
Subject Company was established in 1997 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is good. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.95 |
|
|
1 |
Rs.84.03 |
|
Euro |
1 |
Rs.70.72 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.